Episurf Medical: Q1’22 Review

Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Episurf Medical: Q1’22 Review

OB

Oscar Bergman

Episurf Medical

2.185

▼ 0.06

-2.89%

Premium Plan required to unlock

Redeye reiterates its fair value range for Episurf Medical following the Q1’22 report and notes several crucial activities carried out that should ignite a more significant sales growth beyond 2022.

Disclosures and disclaimers

Episurf Medical

2.185

▼ 0.06

-2.89%

Premium Plan required to unlock